Epigenetics in drug disposition & drug therapy: symposium report of the 24^th North American meeting of the International Society for the Study of Xenobiotics (ISSX)

References

• Agundez JA. 2004. Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab. 5(3):211–224.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Zhou Z, Zhou J, Chen SQ. 2016. Pharmacogenomics of drug metabolizing enzymes and transporters: relevance to precision medicine. Genom Proteom Bioinf. 14(5):298–313.
   PubMed Web of Science ®Google Scholar
• Baek D, Villen J, Shin C, Camargo FD, Gygi SP, Bartel DP. 2008. The impact of microRNAs on protein output. Nature. 455(7209):64–71.
   PubMed Web of Science ®Google Scholar
• Balkrishna D, Sumant O. 2022. Epigenetics market by products (kits, reagents, enzymes, instruments), by application (oncology, non oncology), by end user (academic and research institutes, pharmaceutical and biotechnology companies, contract research organizations): global opportunity analysis and industry forecast, 2020-2030. Portland, OR: Allied Market Research; [accessed 2022 April 28]. https://www.alliedmarketresearch.com/epigenetics-market.
   Google Scholar
• Balliet RM, Chen G, Gallagher CJ, Dellinger RW, Sun D, Lazarus P. 2009. Characterization of UGTs active against SAHA and association between SAHA glucuronidation activity phenotype with UGT genotype. Cancer Res. 69(7):2981–2989.
   PubMed Web of Science ®Google Scholar
• Bayoumi A, Grønbæk H, George J, Eslam M. 2020. The epigenetic drug discovery landscape for metabolic-associated fatty liver disease. Trends Genet. 36(6):429–441.
   PubMed Web of Science ®Google Scholar
• Belanger A, Hum DW, Beaulieu M, Levesque E, Guillemette C, Tchernof A, Belanger G, Turgeon D, Dubois S. 1998. Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues. J Steroid Biochem Mol Biol. 65(1–6):301–310.
   PubMed Web of Science ®Google Scholar
• Benayoun BA, Pollina EA, Brunet A. 2015. Epigenetic regulation of ageing: linking environmental inputs to genomic stability. Nat Rev Mol Cell Biol. 16(10):593–610.
   PubMed Web of Science ®Google Scholar
• Bolha L, Ravnik-Glavač M, Glavač D. 2017. Long noncoding RNAs as biomarkers in cancer. Dis Markers. 2017:7243968.
   Google Scholar
• Bonder MJ, Kasela S, Kals M, Tamm R, Lokk K, Barragan I, Buurman WA, Deelen P, Greve JW, Ivanov M, et al. 2014. Genetic and epigenetic regulation of gene expression in fetal and adult human livers. BMC Genomics. 15(1):860.
   PubMed Web of Science ®Google Scholar
• Bosma PJ, Seppen J, Goldhoorn B, Bakker C, Oude Elferink RP, Chowdhury JR, Chowdhury NR, Jansen PL. 1994. Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem. 269(27):17960–17964.
   PubMed Web of Science ®Google Scholar
• Budnitz DS, Lovegrove MC, Shehab N, Richards CL. 2011. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 365(21):2002–2012.
   PubMed Web of Science ®Google Scholar
• Carthew RW, Sontheimer EJ. 2009. Origins and mechanisms of miRNAs and siRNAs. Cell. 136(4):642–655.
   PubMed Web of Science ®Google Scholar
• Cascorbi I, Schwab M. 2016. Epigenetics in drug response. Clin Pharmacol Ther. 99(5):468–470.
   PubMed Web of Science ®Google Scholar
• Chen L, Bao Y, Piekos SC, Zhu K, Zhang L, Zhong XB. 2018. A transcriptional regulatory network containing nuclear receptors and long noncoding RNAs controls basal and drug-induced expression of cytochrome P450s in HepaRG cells. Mol Pharmacol. 94(1):749–759.
   PubMed Web of Science ®Google Scholar
• Chen L, Wang P, Manautou JE, Zhong XB. 2020. Knockdown of long noncoding RNAs hepatocyte nuclear factor 1α antisense RNA 1 and hepatocyte nuclear factor 4α antisense RNA 1 alters susceptibility of acetaminophen-induced cytotoxicity in HepaRG cells. Mol Pharmacol. 97(4):278–286.
   PubMed Web of Science ®Google Scholar
• Chen Y, Zeng L, Wang Y, Tolleson WH, Knox B, Chen S, Ren Z, Guo L, Mei N, Qian F, et al. 2017. The expression, induction and pharmacological activity of CYP1A2 are post-transcriptionally regulated by microRNA hsa-miR-132-5p. Biochem Pharmacol. 145:178–191.
   PubMed Web of Science ®Google Scholar
• Cheng G. 2015. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 81:75–93.
   PubMed Web of Science ®Google Scholar
• Condrat CE, Thompson DC, Barbu MG, Bugnar OL, Boboc A, Cretoiu D, Suciu N, Cretoiu SM, Voinea SC. 2020. miRNAs as biomarkers in disease: Latest findings regarding their role in diagnosis and prognosis. cells. 9(2):276.
   Google Scholar
• Court MH, Duan SX, von Moltke LL, Greenblatt DJ, Patten CJ, Miners JO, Mackenzie PI. 2001. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J Pharmacol Exp Ther. 299(3):998–1006.
   PubMed Web of Science ®Google Scholar
• Court MH, Von Moltke LL, Shader RI, Greenblatt DJ. 1997. Biotransformation of chlorzoxazone by hepatic microsomes from humans and ten other mammalian species. Biopharm Drug Dispos. 18(3):213–226.
   PubMed Web of Science ®Google Scholar
• Dannenberg LO, Edenberg HJ. 2006. Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation. BMC Genomics. 7(1):181.
   PubMed Web of Science ®Google Scholar
• Dluzen DF, Lazarus P. 2015. MicroRNA regulation of the major drug-metabolizing enzymes and related transcription factors. Drug Metab Rev. 47(3):320–334.
   PubMed Web of Science ®Google Scholar
• Dluzen DF, Sutliff AK, Chen G, Watson CJ, Ishmael FT, Lazarus P. 2016. Regulation of UGT2B expression and activity by miR-216b-5p in liver cancer cell lines. J Pharmacol Exp Ther. 359(1):182–193.
   PubMed Web of Science ®Google Scholar
• Einolf HJ, Chen L, Fahmi OA, Gibson CR, Obach RS, Shebley M, Silva J, Sinz MW, Unadkat JD, Zhang L, et al. 2014. Evaluation of various static and dynamic modeling methods to predict clinical CYP3A induction using in vitro CYP3A4 mRNA induction data. Clin Pharmacol Ther. 95(2):179–188.
   PubMed Web of Science ®Google Scholar
• Feil R, Fraga MF. 2012. Epigenetics and the environment: emerging patterns and implications. Nat Rev Genet. 13(2):97–109.
   PubMed Web of Science ®Google Scholar
• Feinberg AP. 2007. Phenotypic plasticity and the epigenetics of human disease. Nature. 447(7143):433–440.
   PubMed Web of Science ®Google Scholar
• Fisel P, Schaeffeler E, Schwab M. 2016. DNA methylation of ADME genes. Clin Pharmacol Ther. 99(5):512–527.
   PubMed Web of Science ®Google Scholar
• Fowler S, Morcos PN, Cleary Y, Martin-Facklam M, Parrott N, Gertz M, Yu L. 2017. Progress in prediction and interpretation of clinically relevant metabolic drug-drug interactions: a minireview illustrating recent developments and current opportunities. Curr Pharmacol Rep. 3(1):36–49.
   PubMedGoogle Scholar
• Fraga MF, Esteller M. 2007. Epigenetics and aging: the targets and the marks. Trends Genet. 23(8):413–418.
   PubMed Web of Science ®Google Scholar
• Guo H, Ingolia NT, Weissman JS, Bartel DP. 2010. Mammalian microRNAs predominantly act to decrease target mRNA levels. Nature. 466(7308):835–840.
   PubMed Web of Science ®Google Scholar
• Habano W, Kawamura K, Iizuka N, Terashima J, Sugai T, Ozawa S. 2015. Analysis of DNA methylation landscape reveals the roles of DNA methylation in the regulation of drug metabolizing enzymes. Clin Epigenetics. 7:105.
   PubMed Web of Science ®Google Scholar
• Handel AE, Ebers GC, Ramagopalan SV. 2010. Epigenetics: molecular mechanisms and implications for disease. Trends Mol Med. 16(1):7–16.
   PubMed Web of Science ®Google Scholar
• Hannon E, Lunnon K, Schalkwyk L, Mill J. 2015. Interindividual methylomic variation across blood, cortex, and cerebellum: implications for epigenetic studies of neurological and neuropsychiatric phenotypes. Epigenetics. 10(11):1024–1032.
   PubMed Web of Science ®Google Scholar
• Heerboth S, Lapinska K, Snyder N, Leary M, Rollinson S, Sarkar S. 2014. Use of epigenetic drugs in disease: an overview. Genet Epigenet. 6:9–19.
   PubMedGoogle Scholar
• Honkakoski P, Negishi M. 2000. Regulation of cytochrome P450 (CYP) genes by nuclear receptors. Biochem J. 347(Pt 2):321–337.
   PubMed Web of Science ®Google Scholar
• Horvath S. 2013. DNA methylation age of human tissues and cell types. Genome Biol. 14(10):R115.
   PubMed Web of Science ®Google Scholar
• Huntzinger E, Izaurralde E. 2011. Gene silencing by microRNAs: contributions of translational repression and mRNA decay. Nat Rev Genet. 12(2):99–110.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M, Zhong XB, Hankinson O, Beedanagari S, Yu AM, Peng L, Osawa Y. 2013. Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport. Drug Metab Dispos. 41(10):1725–1731.
   PubMed Web of Science ®Google Scholar
• Jin Y, Yu D, Tolleson WH, Knox B, Wang Y, Chen S, Ren Z, Deng H, Guo Y, Ning B. 2016. MicroRNA hsa-miR-25-3p suppresses the expression and drug induction of CYP2B6 in human hepatocytes. Biochem Pharmacol. 113:88–96.
   PubMed Web of Science ®Google Scholar
• Komagata S, Nakajima M, Takagi S, Mohri T, Taniya T, Yokoi T. 2009. Human CYP24 catalyzing the inactivation of calcitriol is post-transcriptionally regulated by miR-125b. Mol Pharmacol. 76(4):702–709.
   PubMed Web of Science ®Google Scholar
• Kringel D, Malkusch S, Lötsch J. 2021. Drugs and epigenetic molecular functions. a pharmacological data scientometric analysis. IJMS. 22(14):7250.
   Web of Science ®Google Scholar
• Kronfol MM, Abudahab S, Dozmorov MG, Jahr FM, Halquist MS, McRae M, Wijesinghe DS, Price ET, Slattum PW, McClay JL. 2021. Histone acetylation at the sulfotransferase 1a1 gene is associated with its hepatic expression in normal aging. Pharmacogenet Genomics. 31(9):207–214.
   PubMed Web of Science ®Google Scholar
• Kronfol MM, Dozmorov MG, Huang R, Slattum PW, McClay JL. 2017. The role of epigenomics in personalized medicine. Expert Rev Precis Med Drug Dev. 2(1):33–45.
   PubMed Web of Science ®Google Scholar
• Kronfol MM, Jahr FM, Dozmorov MG, Phansalkar PS, Xie LY, Aberg KA, McRae M, Price ET, Slattum PW, Gerk PM, et al. 2020. DNA methylation and histone acetylation changes to cytochrome P450 2E1 regulation in normal aging and impact on rates of drug metabolism in the liver. Geroscience. 42(3):819–832.
   PubMed Web of Science ®Google Scholar
• Lauschke VM, Zhou Y, Ingelman-Sundberg M. 2019. Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity. Pharmacol Ther. 197:122–152.
   PubMed Web of Science ®Google Scholar
• Li E. 2002. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet. 3(9):662–673.
   PubMed Web of Science ®Google Scholar
• Li D, Knox B, Chen S, Wu L, Tolleson WH, Liu Z, Yu D, Guo L, Tong W, Ning B. 2019a. MicroRNAs hsa-miR-495-3p and hsa-miR-486-5p suppress basal and rifampicin-induced expression of human sulfotransferase 2A1 (SULT2A1) by facilitating mRNA degradation. Biochem Pharmacol. 169:113617.
   PubMed Web of Science ®Google Scholar
• Li D, Knox B, Gong B, Chen S, Guo L, Liu Z, Tong W, Ning B. 2021. Identification of translational microRNA biomarker candidates for ketoconazole-induced liver injury using next-generation sequencing. Toxicol Sci. 179(1):31–43.
   PubMed Web of Science ®Google Scholar
• Li Y, Li Y, Zheng G, Zhu L, Wang J, Mu S, Ren Q, Feng F. 2018. Cytochrome P450 1A1 and 1B1 promoter CpG island methylation regulates rat liver injury induced by isoniazid. Mol Med Rep. 17(1):753–762.
   PubMed Web of Science ®Google Scholar
• Li D, Tolleson WH, Yu D, Chen S, Guo L, Xiao W, Tong W, Ning B. 2019b. Regulation of cytochrome P450 expression by microRNAs and long noncoding RNAs: Epigenetic mechanisms in environmental toxicology and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev. 37(3):180–214.
   PubMed Web of Science ®Google Scholar
• Li D, Wu L, Knox B, Chen S, Tolleson WH, Liu F, Yu D, Guo L, Tong W, Ning B. 2020. Long noncoding RNA LINC00844-mediated molecular network regulates expression of drug metabolizing enzymes and nuclear receptors in human liver cells. Arch Toxicol. 94(5):1637–1653.
   PubMed Web of Science ®Google Scholar
• Lowe R, Slodkowicz G, Goldman N, Rakyan VK. 2015. The human blood DNA methylome displays a highly distinctive profile compared with other somatic tissues. Epigenetics. 10(4):274–281.
   PubMed Web of Science ®Google Scholar
• Lu C, Di L. 2020. In vitro and in vivo methods to assess pharmacokinetic drug- drug interactions in drug discovery and development. Biopharm Drug Dispos. 41(1–2):3–31.
   PubMed Web of Science ®Google Scholar
• McClay JL, Aberg KA, Clark SL, Nerella S, Kumar G, Xie LY, Hudson AD, Harada A, Hultman CM, Magnusson PK, et al. 2014. A methylome-wide study of aging using massively parallel sequencing of the methyl-CpG-enriched genomic fraction from blood in over 700 subjects. Hum Mol Genet. 23(5):1175–1185.
   PubMed Web of Science ®Google Scholar
• Miao L, Yao H, Li C, Pu M, Yao X, Yang H, Qi X, Ren J, Wang Y. 2016. A dual inhibition: microRNA-552 suppresses both transcription and translation of cytochrome P450 2E1. Biochim Biophys Acta. 1859(4):650–662.
   PubMed Web of Science ®Google Scholar
• Lorico A, Corbeil D, Pawelek JM, Alessandro R. 2015. Transmission of information in neoplasia by extracellular vesicles. Hindawi. 2015:1–2.
   Web of Science ®Google Scholar
• Mohri T, Nakajima M, Fukami T, Takamiya M, Aoki Y, Yokoi T. 2010. Human CYP2E1 is regulated by miR-378. Biochem Pharmacol. 79(7):1045–1052.
   PubMed Web of Science ®Google Scholar
• Mukherji S, Ebert MS, Zheng GX, Tsang JS, Sharp PA, van Oudenaarden A. 2011. MicroRNAs can generate thresholds in target gene expression. Nat Genet. 43(9):854–859.
   PubMed Web of Science ®Google Scholar
• Nagar S, Remmel RP. 2006. Uridine diphosphoglucuronosyltransferase pharmacogenetics and cancer. Oncogene. 25(11):1659–1672.
   PubMed Web of Science ®Google Scholar
• Nakano M, Mohri T, Fukami T, Takamiya M, Aoki Y, McLeod HL, Nakajima M. 2015. Single-nucleotide polymorphisms in cytochrome P450 2E1 (CYP2E1) 3’-untranslated region affect the regulation of CYP2E1 by miR-570. Drug Metab Dispos. 43(10):1450–1457.
   PubMed Web of Science ®Google Scholar
• Nguyen KV. 2019. Potential epigenomic co-management in rare diseases and epigenetic therapy. Nucleosides Nucleotides Nucleic Acids. 38(10):752–780.
   PubMed Web of Science ®Google Scholar
• Ning B, Yu D, Yu AM. 2019. Advances and challenges in studying noncoding RNA regulation of drug metabolism and development of RNA therapeutics. Biochem Pharmacol. 169:113638.
   PubMed Web of Science ®Google Scholar
• Pan YZ, Gao W, Yu AM. 2009. MicroRNAs regulate CYP3A4 expression via direct and indirect targeting. Drug Metab Dispos. 37(10):2112–2117.
   PubMed Web of Science ®Google Scholar
• Pan X, Kent R, Won KJ, Jeong H. 2017. Cholic acid feeding leads to increased CYP2D6 expression in CYP2D6-humanized mice. Drug Metab Dispos. 45(4):346–352.
   PubMed Web of Science ®Google Scholar
• Peters MJ, Joehanes R, Pilling LC, Schurmann C, Conneely KN, Powell J, Reinmaa E, Sutphin GL, Zhernakova A, Schramm K, et al. 2015. The transcriptional landscape of age in human peripheral blood. Nat Commun. 6:8570.
   PubMed Web of Science ®Google Scholar
• Prachayasittikul V, Prathipati P, Pratiwi R, Phanus-Umporn C, Malik AA, Schaduangrat N, Seenprachawong K, Wongchitrat P, Supokawej A, Prachayasittikul V, et al. 2017. Exploring the epigenetic drug discovery landscape. Expert Opin Drug Discov. 12(4):345–362.
   PubMed Web of Science ®Google Scholar
• Rasool M, Malik A, Naseer MI, Manan A, Ansari S, Begum I, Qazi MH, Pushparaj P, Abuzenadah AM, Al-Qahtani MH, et al. 2015. The role of epigenetics in personalized medicine: challenges and opportunities. BMC Med Genomics. 8(Suppl 1):S5.
   PubMed Web of Science ®Google Scholar
• Reynolds LM, Taylor JR, Ding J, Lohman K, Johnson C, Siscovick D, Burke G, Post W, Shea S, Jacobs DR Jr, et al. 2014. Age-related variations in the methylome associated with gene expression in human monocytes and T cells. Nat Commun. 5:5366.
   PubMed Web of Science ®Google Scholar
• Routledge PA, O’Mahony MS, Woodhouse KW. 2004. Adverse drug reactions in elderly patients. Br J Clin Pharmacol. 57(2):121–126.
   PubMed Web of Science ®Google Scholar
• Russell LE, Zhou Y, Almousa AA, Sodhi JK, Nwabufo CK, Lauschke VM. 2021. Pharmacogenomics in the era of next generation sequencing– from byte to bedside. Drug Metab Rev. 53(2):253–278.
   PubMed Web of Science ®Google Scholar
• Savolainen VT, Pajarinen J, Perola M, Penttilä A, Karhunen PJ. 1997. Polymorphism in the cytochrome P450 2E1 gene and the risk of alcoholic liver disease. J Hepatol. 26(1):55–61.
   PubMed Web of Science ®Google Scholar
• Selbach M, Schwanhausser B, Thierfelder N, Fang Z, Khanin R, Rajewsky N. 2008. Widespread changes in protein synthesis induced by microRNAs. Nature. 455(7209):58–63.
   PubMed Web of Science ®Google Scholar
• Sim SC, Kacevska M, Ingelman-Sundberg M. 2013. Pharmacogenomics of drug-metabolizing enzymes: a recent update on clinical implications and endogenous effects. Pharmacogenomics J. 13(1):1–11.
   PubMed Web of Science ®Google Scholar
• Steegenga WT, Boekschoten MV, Lute C, Hooiveld GJ, de Groot PJ, Morris TJ, Teschendorff AE, Butcher LM, Beck S, Müller M. 2014. Genome-wide age-related changes in DNA methylation and gene expression in human PBMCs. Age (Dordr). 36(3):9648.
   PubMedGoogle Scholar
• Stern AM, Schurdak ME, Bahar I, Berg JM, Taylor DL. 2016. A perspective on implementing a quantitative systems pharmacology platform for drug discovery and the advancement of personalized medicine. J Biomol Screen. 21(6):521–534.
   PubMedGoogle Scholar
• Stricker SH, Köferle A, Beck S. 2017. From profiles to function in epigenomics. Nat Rev Genet. 18(1):51–66.
   PubMed Web of Science ®Google Scholar
• Sun D, Jones NR, Manni A, Lazarus P. 2013. Characterization of raloxifene glucuronidation: potential role of UGT1A8 genotype on raloxifene metabolism in vivo. Cancer Prev Res. 6(7):719–730.
   PubMed Web of Science ®Google Scholar
• Sutliff AK, Shi J, Watson CJW, Hunt MS, Chen G, Zhu HJ, Lazarus P. 2019. Potential regulation of UGT2B10 and UGT2B7 by miR-485-5p in human liver. Mol Pharmacol. 96(6):674–682.
   PubMed Web of Science ®Google Scholar
• Takagi S, Nakajima M, Mohri T, Yokoi T. 2008. Post-transcriptional regulation of human pregnane X receptor by micro-RNA affects the expression of cytochrome P450 3A4. J Biol Chem. 283(15):9674–9680.
   PubMed Web of Science ®Google Scholar
• Tang X, Chen S. 2015. Epigenetic regulation of cytochrome P450 enzymes and clinical implication. Curr Drug Metab. 16(2):86–96.
   PubMed Web of Science ®Google Scholar
• Treyer A, Ullah M, Parrott N, Molitor B, Fowler S, Artursson P. 2019. Impact of intracellular concentrations on metabolic drug-drug interaction studies. Aaps J. 21(5):1–10.
   Web of Science ®Google Scholar
• Tseng E, Eng H, Lin J, Cerny MA, Tess DA, Goosen TC, Obach RS. 2021. Static and dynamic projections of drug-drug interactions caused by cytochrome P450 3A time-dependent inhibitors measured in human liver microsomes and hepatocytes. Drug Metab Dispos. 49(10):947–960.
   PubMedGoogle Scholar
• Tsuchiya Y, Nakajima M, Takagi S, Taniya T, Yokoi T. 2006. MicroRNA regulates the expression of human cytochrome P450 1B1. Cancer Res. 66(18):9090–9098.
   PubMed Web of Science ®Google Scholar
• Wang J, Yu L, Jiang H, Zheng X, Zeng S. 2020. Epigenetic regulation of differentially expressed drug-metabolizing enzymes in cancer. Drug Metab Dispos. 48(9):759–768.
   PubMed Web of Science ®Google Scholar
• Wang Y, Yu D, Tolleson WH, Yu LR, Green B, Zeng L, Chen Y, Chen S, Ren Z, Guo L, et al. 2017. A systematic evaluation of microRNAs in regulating human hepatic CYP2E1. Biochem Pharmacol. 138:174–184.
   PubMed Web of Science ®Google Scholar
• Winkle M, El-Daly SM, Fabbri M, Calin GA. 2021. Noncoding RNA therapeutics – challenges and potential solutions. Nat Rev Drug Discov. 20(8):629–651.
   PubMed Web of Science ®Google Scholar
• Yadav J, Korzekwa K, Nagar S. 2018. Improved predictions of drug–drug interactions mediated by time-dependent inhibition of CYP3A. Mol Pharm. 15(5):1979–1995.
   PubMed Web of Science ®Google Scholar
• Yadav J, Paragas E, Korzekwa K, Nagar S. 2020. Time-dependent enzyme inactivation: numerical analyses of in vitro data and prediction of drug-drug interactions. Pharmacol Ther. 206:107449.
   PubMed Web of Science ®Google Scholar
• Yu D, Chen S, Li D, Knox B, Guo L, Ning B. 2020. FREMSA: a method that provides direct evidence of the interaction between microRNA and mRNA. Methods Mol Biol. 2102:557–566.
   PubMedGoogle Scholar
• Yu D, Green B, Marrone A, Guo Y, Kadlubar S, Lin D, Fuscoe J, Pogribny I, Ning B. 2015. Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma. Sci Rep. 5:8534.
   PubMed Web of Science ®Google Scholar
• Yu D, Wu L, Gill P, Tolleson WH, Chen S, Sun J, Knox B, Jin Y, Xiao W, Hong H, et al. 2018. Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 92(2):845–858.
   PubMed Web of Science ®Google Scholar
• Zanger UM, Schwab M. 2013. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 138(1):103–141.
   PubMed Web of Science ®Google Scholar
• Zeng L, Chen Y, Wang Y, Yu LR, Knox B, Chen J, Shi T, Chen S, Ren Z, Guo L, et al. 2017. MicroRNA hsa-miR-370-3p suppresses the expression and induction of CYP2D6 by facilitating mRNA degradation. Biochem Pharmacol. 140:139–149.
   PubMed Web of Science ®Google Scholar
• Zeng L, Li D, Tong W, Shi T, Ning B. 2021. Biochemical features and mutations of key proteins in SARS-CoV-2 and their impacts on RNA therapeutics. Biochem Pharmacol. 189:114424.
   PubMed Web of Science ®Google Scholar
• Zhou SF, Liu JP, Chowbay B. 2009. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 41(2):89–295.
   PubMed Web of Science ®Google Scholar